PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112567
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 2112567
The global empty capsules market was valued at USD 3.4 billion in 2025 and is projected to reach USD 5.6 billion by 2032, growing at a CAGR of 7.3% between 2026 and 2032. Growth is being driven by rising demand for gelatin and non-gelatin capsule shells across pharmaceutical, nutraceutical, and cosmeceutical manufacturing, as manufacturers favor hard capsules for formulation flexibility and taste-masking capability.
Aging populations underpin much of this demand. The global population aged 60 years and older will increase from 1 billion in 2020 to 1.4 billion by 2030, according to the World Health Organization, driving chronic disease therapy needs that rely on capsule-based oral medications.
Supplement consumption is a growing pillar too. 60.2% of adults aged 20 years and older used a dietary supplement in the past 30 days during 2021-2023, according to the CDC's National Center for Health Statistics, reinforcing demand for empty capsules in nutraceutical manufacturing.
Key Insights
Gelatin Capsules hold the larger type share, at 75%, given cost-effective production and rapid dissolution; the FDA's Inactive Ingredient Database lists gelatin as an approved excipient reflecting longstanding regulatory acceptance. Non-Gelatin Capsules post the higher CAGR, at approximately 7.6%, driven by vegetarian, vegan, and halal compliance demand.
Immediate-Release Capsules hold the largest functionality share, at 60%, given rapid drug release and cost-effective manufacturing. Delayed-Release Capsules post the highest CAGR, driven by increasing use of probiotics and acid-sensitive drugs requiring intestinal release.
Antibiotic Drugs are the largest application at 45% share; U.S. healthcare providers issued 255.9 million oral antibiotic prescriptions in 2024, according to the CDC. Dietary Supplements post the highest CAGR, as supplement use among U.S. adults increased from 51.8% in 2011-2012 to 61.4% in 2021-2023, according to a NHANES trend analysis.
Pharmaceutical Industry holds the largest end-user share, at 40%; U.S. retail prescription drug spending increased 7.9% to USD 467.0 billion in 2024, according to CMS. Nutraceutical Industry posts the highest CAGR, at approximately 7.9%; 38.7% of U.S. adults used two or more dietary supplements during 2021-2023, according to the NCHS.
North America holds the largest regional share, at 40%, supported by a dense concentration of contract development and manufacturing organizations. The FDA approved 694 abbreviated new drug applications in fiscal year 2024, reflecting sustained generic drug development.
Canada shows significant growth potential, driven by increasing investment in pharmaceutical and vitamin supplement manufacturing alongside rising chronic disease prevalence.
Asia-Pacific posts the highest regional CAGR, at approximately 8.2%, driven by expanding pharmaceutical and nutraceutical manufacturing capacity in China and India, supported by government initiatives promoting domestic production.
Plant-based capsule materials represent a defining trend, as formulators shift from animal-derived gelatin toward HPMC shells. ACG introduced vegan printed capsules made from plant-derived HPMC polymers in February 2025, certified by Vegan Action and The Vegetarian Society.
Rising chronic disease burden remains the biggest driver. Noncommunicable diseases caused at least 43 million deaths in 2021, accounting for 75% of non-pandemic-related deaths globally, according to the WHO.
Livestock supply contraction is the main restraint, tightening bovine gelatin availability. The U.S. cattle inventory fell to 86.7 million head as of January 2025, the lowest level since 1951, according to the USDA's National Agricultural Statistics Service.
Government incentives create a clear opportunity for specialty capsule manufacturing. India's Production Linked Incentive Scheme carries a total outlay of INR 15,000 crore, identifying special empty capsules like HPMC and Pullulan as a Category 1 eligible product group.
The competitive landscape spans established gelatin and HPMC capsule manufacturers expanding across global production hubs. Recent activity includes ACG's commencement of operations at a new 175,000-square-meter capsule manufacturing facility in Rayong, Thailand, in December 2024, with an annual production capacity of 20 billion capsules.